Prospective Study of Fungaemia in a Single Cancer Institution over a 10-y Period: Aetiology, Risk Factors, Consumption of Antifungals and Outcome in 140 Patients

References

• Rex J, and the Candidemia Study Group. A randomised trial comparing fluconazole vs. amphotericin B for the treatment of Candidemia. N Engl J Med 1994; 331: 1325–30.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Girmenia G, Martino P, Marinus A, Colette I, Ellis F, et al. European study on candidemia in cancer patients. Clin Infect Dis 1999; 22: 133–50.
   Google Scholar
• Wey SB, Mori M, Pfaller MRF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642–55.
   PubMed Web of Science ®Google Scholar
• Fraser VJ, Dunagan WC. Candidemia in a tertiary care hospital. Epidemiology, risk factors and predictors of mortality. Clin Inf Dis 1992; 15: 414–21.
   Google Scholar
• Harvey RL, Myers JP. Nosocomial fungaemia in a large community teaching hospital. Arch Intern Med 1987; 147: 2117–20.
   PubMedGoogle Scholar
• Goodman J, Winston DJ, Greenfield RA and BMT cooperative group. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–51.
   Google Scholar
• Link H, Ernst P, Spenee D. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematologic malignancies. Eur J Clin Microbiol Inf Dis 1994; 13: 3–11.
   Google Scholar
• Wingard JR. Importance of Candida spp. other than C. albicans in cancer patients. Antimicrob Agents Chemother 1995; 12: 133–9.
   Google Scholar
• Rex J, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1–8.
   PubMed Web of Science ®Google Scholar
• Kunová A, Trupl J, Spanik S, Drgona L, Sufliarsky J, Lacka J, et al. Candida glabrata, Candida krusei, non-albicans Candida spp. and other fungal organisms in a sixty bed national cancer center in 1989–1993: no association with the use of fluconazole. Chemotherapy 1995; 41: 39–44.
   Google Scholar
• Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818–29.
   PubMed Web of Science ®Google Scholar
• Horn R, Wong B, Kiehn TE, Armstrong D. Fungaemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985; 7: 646–55.
   PubMedGoogle Scholar
• Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungaemia caused by Candida species and Torulopsis glabrata in the hospitalised patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11: 379–90.
   PubMedGoogle Scholar
• Van t Wout JW. Fluconazole treatment of Candidal infections caused by non-albicans species. Eur J Clin Microbiol Infect Dis 1996; 15: 362–3.
   Google Scholar
• Edwards JE Jr. Should all patients with candidemia be treated with antifungal agents? Clin Infect Dis 1992; 15: 422–3.
   PubMedGoogle Scholar
• Krajcik S. Infections and pharmacotherapy in elderly. Geriatrics 1998; 3: 33.
   Google Scholar
• Annaissie E, Bodey GP. Trichisporonosis – meeting the challenge. Eur J Clin Microbiol Inf Dis 1991; 10: 711.
   PubMedGoogle Scholar
• Guiot H, Fibbe W. Risk factors for fungal infections in patients with malignant haematologic disorders. Clin Inf Dis 1994; 18: 525–32.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Donelly JP, Kullberg BJ, Meis JFGM, De Pauw BE. Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infections 1994; 22: 81–5.
   Google Scholar
• Goldman M, Pottage J, Weaver DC. Candida krusei fungaemia. Medicine (Baltimore) 1993; 72: 143–50.
   PubMed Web of Science ®Google Scholar
• McQuillen D, Zingman SB, Meunier F, Levitz S. Invasive infections due to C. krusei. Clin Inf Dis 1992; 14: 472–8.
   PubMed Web of Science ®Google Scholar
• McCabe WR, Jackson GG. Prognostic factors of underlying disease. Arch Int Med 1962; 110: 847–55.
   Google Scholar
• Walsh T, Pizzo P. Fungaemia in HIV-positive children. Clin Inf Dis 1996; 20: 732–40.
   Google Scholar
• Lecciones J, Lee LW, Navaro EE, Witebsky F, Marshall D, Steinberg S, et al. Catheter associated fungaemia in cancer patients. Analysis of 155 episodes. Clin Inf Dis 1996; 20: 334–5.
   Google Scholar
• Kim-Stamos J, Rowley AH. Candidaemia in a paediatric population. Clin Inf Dis 1995; 20: 571–5.
   Google Scholar
• Abi-Said D, Annaisie E, Uzun D, Raad I, Pinczowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by Candida spp. Clin Inf Dis 1997; 24: 1122–9.
   Google Scholar
• White M. Epidemiology of invasive candidiasis. Int J Infect Dis 1997; 51: 7–10.
   Google Scholar
• Bow E. Documented fungal infections after chemotherapy for acute leukemia. Clin Inf Dis 1997; 24: 394–401.
   Google Scholar
• Demitrovicova A, Kralovicova K, Kunova A, Trupl J. Bacteremia and fungemia after antineoplastic chemotherapy – association between cytotoxics and particular pathogen. Anti-infect Drugs Chemother 1997; 20: 26–8.
   Google Scholar
• Pfaller M and the SENTRY study group. Results from the surveillance of fungaemia (SENTRY) in United States, Canada and South America. Antimicrob Agents Chemother 2000; 44: 214–6.
   Google Scholar